Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer - Trial NCT06391034
Access comprehensive clinical trial information for NCT06391034 through Pure Global AI's free database. This Phase 2 trial is sponsored by Robert Bok, MD, PhD and is currently Not yet recruiting. The study focuses on Prostate Cancer. Target enrollment is 161 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Robert Bok, MD, PhD
University of California, San Francisco
Timeline & Enrollment
Phase 2
Jun 01, 2024
Jun 30, 2032
Primary Outcome
Signal-to-noise ratio (Part 1),Mean HP 13C-pyruvate to lactate metabolic rate of conversion (kPL) over time (Part 2A),Mean HP 13C-pyruvate to glutamate metabolic rate of conversion (kPG) over time (Part 2A),Mean change in on-treatment kPL over time (Part 2B),Mean change in on-treatment kPG over time (Part 2B),Mean kPL at time of biochemical failure (Part 3),Mean kPG at time of biochemical failure (Part 3)
Summary
This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea
 (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have
 received radiation therapy for prostate cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06391034
Non-Device Trial